A large-scale analysis has revealed independently validated gut biomarkers that can distinguish patients with inflammatory ...

2月25日，强生公司在北京宣布特诺雅达（古塞奇尤单抗注射液（静脉输注））和特诺雅（古塞奇尤单抗注射液）在中国获得批准，标志着古塞奇尤单抗在克罗恩病适应症上的全球首个批准，该药用于治疗对传统治疗或生物制剂应答不充分、失应答或不耐受的中度至重度活动性克罗 ...

东方网记者刘轶琳2月25日报道：克罗恩病是炎症性肠病（Inflammatory Bowel Disease, IBD）的两种主要亚型之一，是一种慢性消化道炎症性疾病，严重影响着全球数百万人的健康。在过去几十年中，中国克罗恩病的发病率持续上升，每10万人的年发病率约为0.51-1.09，发病高峰年龄集中在20至30岁之间。

For more than a decade, Michelle Hobson endured extreme fatigue, excruciating abdominal pain, and repeated hospital visits.

为解决 IBD 诊断和亚型区分难题，韩国庆熙大学研究人员开展血清代谢组学研究。结果发现特定血清代谢物可精准识别 IBD 及亚型。这一成果对提升 IBD 诊疗水平意义重大，强烈推荐科研读者阅读。

A British study found that virtual chromoendoscopy has a higher neoplasia detection rate than other endoscopic modalities ...

Up to 40% of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), with the ...

文章中，研究者发现，名为万古霉素（vancomycin）的抗生素或能有效治疗患有特定类型炎性肠病（IBD）的患者，这种疾病会在一种无法治愈的称之为原发性硬化性胆管炎（PSC，primary sclerosing ...

Ensho Therapeutics has presented additional data supporting NSHO-101, also referred to as EA1080, as an oral one-time-a-day ...

By adjusting the fat levels in mRNA-based drugs, researchers have found a way to bypass the liver and go straight to the ...

The mystery of why people with Inflammatory Bowel Disease (IBD) have a four times higher risk of getting life threatening ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...